Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Income from Continuing Operations (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Income from Continuing Operations for 10 consecutive years, with 7356000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 117.19% to 7356000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10616000.0 through Dec 2025, up 83.7% year-over-year, with the annual reading at 9904000.0 for FY2025, 84.79% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 7356000.0 at Rein Therapeutics, up from 5492000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 7356000.0 in Q4 2025, with the low at 42797000.0 in Q4 2024.
  • Average Income from Continuing Operations over 5 years is 7285000.0, with a median of 6571000.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations plummeted 487.06% in 2024, then surged 117.19% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 6816000.0 in 2021, then skyrocketed by 31.0% to 4703000.0 in 2022, then plummeted by 55.01% to 7290000.0 in 2023, then tumbled by 487.06% to 42797000.0 in 2024, then soared by 117.19% to 7356000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 7356000.0, 5492000.0, and 6871000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.